Elan announced today that the US Food and Drug Administration approved Frova, for the acute treatment of migraine.
Mr Donal Geaney, chairman and chief executive of Elan described the decisoion as a key milestone in advancing Elan’s pipeline of products for neurological disorders.
Approximately 10 per cent of the US population suffer from migraine attacks. The US market in 2001 for migraine therapy is expected to be approximately $1.4 billion.
Elan licensed exclusive North American sales and distribution rights for Frova in October 1998 from the Vernalis Group.
